Connaught and russian strains showed the highest direct antitumor effects of different bacillus calmette-guérin substrains

Journal of Urology

Volumn 189, Issue 2, 2013, Pages 711-718

  Secanella Fandos, Silvia ^a   Luquin, Marina ^a   Julián, Esther ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

BCG vaccine; cell line; immunotherapy; urinary bladder neoplasms; urothelium

Indexed keywords

BCG VACCINE; INTERLEUKIN 6; INTERLEUKIN 8;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL STRAIN; BLADDER CANCER; CANCER CELL CULTURE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SUPERNATANT;

BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; HUMANS; MYCOBACTERIUM BOVIS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 84872152071     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.09.049     Document Type: Article

References (30)

1. M. Babjuk, W. Oosterlinck, R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997
2. M.A. Behr BCG - different strains, different vaccines? Lancet Infect Dis 2 2002 86
3. M. Rodriguez-Alvarez, G. Mendoza-Hernandez, S. Encarnación Phenotypic differences between BCG vaccines at the proteome level Tuberculosis (Edinb) 89 2009 126
4. D. Hayashi, T. Takii, N. Fujiwara Comparable studies of immunostimulating activities in vitro among Mycobacterium bovis bacillus Calmette-Guérin (BCG) substrains FEMS Immunol Med Microbiol 56 2009 116
5. D. Hayashi, T. Takii, T. Mukai Biochemical characteristics among Mycobacterium bovis BCG substrains FEMS Microbiol Lett 306 2010 103
6. J. Liu, V. Tran, A.S. Leung BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy Hum Vaccin 5 2009 70
7. V. Davids, W.A. Hanekom, N. Mansoor The effect of bacille Calmette-Guérin vaccine strain and route of administration on induced immune responses in vaccinated infants J Infect Dis 193 2006 531
8. M.A. Horwitz, G. Harth, B.J. Dillon Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strain of disparate genealogy induce comparable protective immunity against tuberculosis Vaccine 27 2007 441
9. K. Schwarzer, M. Foerster, T. Steiner BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis Cancer Cell Int 10 2010 21
10. E. Rodríguez-Güell, G. Agustí, M. Corominas The production of a new extracellular putative long-chain saturated polyester by smooth variants of Mycobacterium vaccae interferes with Th1-cytokine production Antonie Van Leeuwenhoek 90 2006 93
11. E. Julián, M. Roldán, A. Sánchez-Chardi Microscopic cords, a virulence-related characteristic of Mycobacterium tuberculosis, are also present in nonpathogenic mycobacteria J Bacteriol 192 2010 1751
12. P. Rajala, E. Kaasinen, E. Rintala Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha Urol Res 20 1992 215
13. Y. Zhang, H.E. Khoo, K. Esuvaranathan Effects of bacillus Calmette-Guerin and interferon-alpha-2B on human bladder cancer in vitro Int J Cancer 71 1997 851
14. J. Miyazaki, K. Kawai, T. Oikawa Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette-Guérin through Toll-like receptor signalling BJU Int 97 2006 860
15. D.K. Ahirwar, P.K. Manchanda, R.D. Mittal BCG response prediction with cytokine gene variants and bladder cancer: where we are? J Cancer Res Clin Oncol 137 2011 1729
16. E.C. de Boer, L. Somogyi, G.J. de Ruiter Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer Urol Res 25 1997 31
17. Y. Shintani, Y. Sawada, T. Inagaki Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy Int J Urol 14 2007 140
18. A. DeMichele, A.M. Martin, R. Mick Interleukin-6-174GàC polymorphism is associated with improved outcome in high-risk breast cancer Cancer Res 63 2003 8051
19. R.F. Bevers, K.H. Kurth, D.H. Schamhart Role of urothelial cells in BCG immunotherapy for superficial bladder cancer Br J Cancer 91 2004 607
20. K. Esuvaranathan, A.B. Alexandroff, M. McIntyre Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy J Urol 154 1995 572
21. G.J. Zhang, S.A. Crist, A.K. McKerrow Autocrine IL-6 production by human transitional carcinoma cells upregulates expression of the alpha5beta1 fibronectin receptor J Urol 163 2000 1553
22. T.M. de Reijke, P.C. Vos, E.C. de Boer Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG) Urol Res 21 1993 349
23. B. Schneider, A. Thanhäuser, D. Jocham Specific binding of bacillus Calmette-Guérin to urothelial tumor cells in vitro World J Urol 12 1994 337
24. S.H. Pook, J.N. Rahmat, K. Esuvaranathan Internalization of Mycobacterium bovis, Bacillus Calmette Guerin, by bladder cancer cells is cytotoxic Oncol Rep 18 2007 1315
25. R.F. Bevers, E.C. de Boer, K.H. Kurth BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated bladder cancer cell lines Eur Cytokine Netw 9 1998 181
26. A.R. Zlotta, J.P. Van Vooren, O. Denis What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer? Int J Cancer 87 2000 844
27. D.N. Dao, K. Sweeney, T. Hsu Mycolic acid modification by the mmaA4 gene of M. tuberculosis modulates IL-12 production PLoS Pathog 4 2008 e1000081
28. M.B. Reed, P. Domenech, C. Manca A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response Nature 431 2004 84
29. R.J. Sylvester, A.P. van der Meijden, D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964
30. Birkhäuser F, Rentsch CA, Studer UE, et al. The BCG strain used is relevant for recurrence-free survival: a randomized phase III study comparing Immucyst® versus Oncotice®. Presented at annual congress of European Association of Urology, Paris, France, February 24-28, 2012, abstract 962.